Azithromycin Oral Suspension

Azithromycin is fundamentally classified within the macrolide subclass of antibiotics, specifically distinguished as an azalide. It is predominantly recognized for its potent activity against a wide array of both Gram-positive and Gram-negative bacteria, as well as atypical pathogens. The formulation is primarily indicated for respiratory tract infections, skin structure infections, and specific sexually transmitted diseases. In pediatric populations, the Suspensions format is critical for ensuring compliance and accurate weight-based dosing. By leveraging state-of-the-art liquid manufacturing protocols, our oral suspension mitigates the inherent bitterness of the active pharmaceutical ingredient (API), presenting a highly palatable and effective pediatric solution.

When selecting a third-party contract manufacturing partner, the stability and efficacy of the final formulation are paramount. Saar Biotech operates out of a highly advanced, WHO-GMP certified facility located in the pharmaceutical hub of Baddi, Himachal Pradesh.

Our specialized suspension manufacturing lines feature high-shear homogenization and automated temperature-controlled compounding vessels. This infrastructure guarantees that every batch of Azithromycin suspension achieves optimal particle size distribution, preventing drug settling and ensuring dose uniformity throughout the shelf life of the product. Our robust Quality Control (QC) protocols exceed standard IP/BP monographs, securing our position as the preferred partner for leading Indian pharmaceutical marketing companies.

Azithromycin is widely prescribed across pediatric and adult populations for the management of various infectious etiologies. The suspension is specifically engineered for patient demographics unable to swallow solid dosage forms.

• Acute Otitis Media (AOM): A highly effective first-line or secondary agent for middle ear infections in children, driven by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis.
• Pharyngitis and Tonsillitis: Indicated for acute streptococcal pharyngitis, particularly in patients exhibiting hypersensitivity to beta-lactam antibiotics.
• Community-Acquired Pneumonia (CAP): Provides excellent coverage against atypical pneumonia pathogens such as Mycoplasma pneumoniae and Chlamydophila pneumoniae.
• Uncomplicated Skin and Skin Structure Infections: Effective against Staphylococcus aureus and Streptococcus pyogenes driven dermatological infections.
• Enteric Fever: Often utilized off-label or in specific pediatric protocols for typhoid fever where resistance profiles mandate macrolide intervention.

Pharmacodynamic Mechanism

Azithromycin exerts its bacteriostatic (and occasionally bactericidal) effect by binding to the 50S ribosomal subunit of susceptible microorganisms. This binding physically obstructs the translation process of mRNA, thereby inhibiting RNA-dependent protein synthesis. Unlike traditional erythromycin, azithromycin’s unique azalide structure—featuring a methyl-substituted nitrogen atom incorporated into the lactone ring—confers enhanced acid stability, superior tissue penetration, and an extended half-life.

Manufacturing Integrity

The clinical efficacy of azithromycin is heavily dependent on its dissolution profile. Saar Biotech ensures peak pharmaceutical integrity by utilizing micronized Azithromycin Dihydrate. Our proprietary compounding matrix includes suspending agents and buffering systems that maintain the API in a perfectly deflocculated state. This strict adherence to rheological standards prevents caking and guarantees that each poured dose contains the exact therapeutic concentration of the drug.

Absorption & Distribution

Following oral administration, Azithromycin is rapidly absorbed, bypassing significant destruction by gastric acid due to its specialized structural modifications. It exhibits extraordinary tissue penetration, achieving concentrations in target tissues (such as lungs, tonsils, and prostate) that are 10 to 100 times higher than those observed in serum. The drug is highly concentrated inside macrophages and polymorphonuclear leukocytes, which transport it directly to the site of infection. The extensive volume of distribution and a terminal elimination half-life of approximately 68 hours permit the highly convenient once-daily dosing regimen that defines azithromycin’s clinical utility.

Commercial Viability

For our B2B partners, the pharmacokinetic profile of Azithromycin directly translates into massive commercial appeal. The once-daily dosing requirement (often for just 3 to 5 days) drastically improves patient compliance compared to multi-dose antibiotic regimens. Marketing companies can capitalize on this “short-course, high-efficacy” narrative. Furthermore, our stable suspension formula guarantees an extended shelf life, reducing supply chain wastage and ensuring maximum return on investment for our contract manufacturing clients.

Saar Biotech is structurally optimized to support the high-volume, high-quality demands of modern pharmaceutical marketing networks. We offer end-to-end third-party manufacturing solutions for Azithromycin Oral Suspension.

• Batch Size Flexibility: We accommodate variable batch sizes to support both localized product launches and massive Pan-India distributions.
• Packaging Customizability: The product can be packaged in 15ml, 30ml, or 60ml capacities utilizing high-grade amber PET or glass bottles to protect against photodegradation.
• Private Labeling & Art Design: Our internal regulatory and design teams assist with carton creation, ensuring DCGI and Legal Metrology compliance on all visual assets.
• Taste Masking: We employ advanced masking technologies and premium flavoring agents (such as mixed fruit, strawberry, or peppermint) to completely neutralize the bitter profile of the macrolide ring.

Maintaining the integrity of the suspension is critical for preserving clinical efficacy. The product must be stored in a cool, dry place, strictly below 30°C. It must be protected from direct sunlight and excessive moisture. Once reconstituted (if supplied as a dry syrup) or opened, it is imperative to secure the cap tightly after every use to prevent evaporation and microbial ingress. Patients must be instructed to shake the bottle vigorously before every administration to ensure perfect dose uniformity.

At Saar Biotech, regulatory compliance and biochemical purity are non-negotiable. Every batch of Azithromycin Suspension undergoes a rigorous, multi-tiered testing protocol within our GLP-certified analytical laboratories.

• High-Performance Liquid Chromatography (HPLC): Utilized for precise quantification of the Azithromycin API to ensure it meets strict IP/BP assay specifications (typically 90.0% to 110.0% of the labeled amount).
• Rheological & Viscosity Testing: Ensures the suspension maintains ideal flow properties for pouring while preventing rapid sedimentation.
• pH Analysis: The suspension is strictly buffered to maintain a pH that optimizes the stability of the macrolide structure against hydrolytic degradation.
• Microbial Limit Testing (MLT): Comprehensive screening confirms the absolute absence of pathogenic microorganisms such as E. coli or Salmonella, guaranteeing pediatric safety.
• Accelerated Stability Studies: Conducted in our dedicated stability chambers to validate the assigned shelf life across various climatic zones.

While Azithromycin is globally recognized for its favorable safety profile, professional discretion is required. The most commonly reported adverse events are gastrointestinal in nature, including mild nausea, vomiting, diarrhea, and abdominal pain.

Rare but significant adverse reactions include hepatotoxicity and QT interval prolongation. It should be administered with extreme caution in patients with a known history of severe hepatic impairment or pre-existing proarrhythmic conditions. It is contraindicated in patients with a known hypersensitivity to azithromycin, erythromycin, or any macrolide/ketolide antibiotic. Prescribers must also monitor for potential drug interactions, particularly with agents metabolized by the cytochrome P450 system, though azithromycin demonstrates less CYP450 interference compared to older macrolides.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Azithromycin Oral Suspension, please use the B2B enquiry form below.